Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Ready To Re-Balance? Guidant Deal Would Decrease Dependence On Rx

Executive Summary

Johnson & Johnson's proposed acquisition of Guidant will help the company restore the balance in its health care portfolio

You may also be interested in...



Biotech Exit Strategy Of Choice Is Acquisition, Not IPO, Investor Says

Venture capital firms are increasingly shaping biotech companies to look like acquisition prospects from the outset, rather than candidates for initial public offerings, according to one investor's analysis

Biotech Exit Strategy Of Choice Is Acquisition, Not IPO, Investor Says

Venture capital firms are increasingly shaping biotech companies to look like acquisition prospects from the outset, rather than candidates for initial public offerings, according to one investor's analysis

J&J Sees Rx Synergies In Guidant Deal; Big Buy Does Not Rule Out More Deals

J&J's acquisition of Guidant will open up new areas of opportunity for collaboration between the pharmaceutical, device and diagnostic operations of the company, CEO William Weldon declared during a Dec. 16 analysts conference call

Related Content

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel